TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16977507

Group type: EXPERIMENTAL
Intervention: Sodium alginate
Number of subjects: 203

Group type: COMPARATOR
Intervention: Magaldrate
Number of subjects: 203
Study: 14749454

Group type: EXPERIMENTAL
Intervention: Strontium ranelate (2 g orally per day)
Number of subjects: 1649

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1649
Study: 11705818

Group type: EXPERIMENTAL
Intervention: Conivaptan 20 mg
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Conivaptan 40 mg
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Conivaptan 10 mg
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 9237061

Group type: EXPERIMENTAL
Intervention: Oral calcium supplementation with 2 g calcium per day
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Oral dietary supplementation with 3.8 g of ispaghula husk
Number of subjects: 655

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 655
Study: 7970514

Group type: EXPERIMENTAL
Intervention: Radial 10-0 nylon suture combined with fibrin glue for wound closure
Number of subjects: 153

Group type: COMPARATOR
Intervention: Fibrin glue only for wound closure (control group)
Number of subjects: 153
Study: 2884081

Group type: EXPERIMENTAL
Intervention: Azelastine 4.4 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ketotifen 2.0 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29237800

Group type: EXPERIMENTAL
Intervention: Clinical care plus community-based programming
Number of subjects: 97

Group type: COMPARATOR
Intervention: Clinical care
Number of subjects: 97
Study: 26762743

Group type: EXPERIMENTAL
Intervention: Cisplatin and Pemetrexed (CPx)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Cisplatin and Vinorelbine (CVb)
Number of subjects: 132
Study: 24947792

Group type: EXPERIMENTAL
Intervention: 20,000 IU/week vitamin D3
Number of subjects: 511

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 511
Study: 22898163

Group type: EXPERIMENTAL
Intervention: Intervention (OSNAP)
Number of subjects: 20
Study: 20543994

Group type: EXPERIMENTAL
Intervention: Adolescent sexual and reproductive health intervention (teacher-led, peer-assisted education, youth-friendly health services, community activities, youth condom promotion and distribution)
Number of subjects: 13814
Study: 18656765

Group type: EXPERIMENTAL
Intervention: Dexamethasone injection
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo injection (lidocaine)
Number of subjects: 64
Study: 16162255

Group type: EXPERIMENTAL
Intervention: Migraineurs (MA and MoA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 11497140

Group type: EXPERIMENTAL
Intervention: Backflow technique (10 cm)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Backflow technique (20 cm)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Backflow technique (30 cm)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional sampling
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Backflow technique
Number of subjects: 120
Study: 9603138

Group type: EXPERIMENTAL
Intervention: Zileuton (600 mg)
Number of subjects: 10
Study: 8310508

Group type: EXPERIMENTAL
Intervention: 33B3.1 (10 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: ATG (1 mg/kg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: ATG
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 33B3.1
Number of subjects: 40
Study: 2449506

Group type: EXPERIMENTAL
Intervention: 1000 mg vancomycin infused over 1 h
Number of subjects: 11

Group type: COMPARATOR
Intervention: 500 mg vancomycin infused over 1 h
Number of subjects: 11
Study: 31161343

Group type: EXPERIMENTAL
Intervention: Lacunar infarct with concurrent embolic infarcts
Number of subjects: 244

Group type: COMPARATOR
Intervention: Lacunar infarct only
Number of subjects: 244
Study: 29555621

Group type: EXPERIMENTAL
Intervention: Mobile Insulin Titration Intervention (MITI) program
Number of subjects: 113
Study: 28919708

Group type: EXPERIMENTAL
Intervention: AOS group (AG, oral administration 10‐mg AOS daily)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Control group (CG, placebo daily)
Number of subjects: 248
Study: 22988961

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES) in blacks
Number of subjects: 2597

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES) in whites
Number of subjects: 2597

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES) in Asians
Number of subjects: 2597

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES) in all groups
Number of subjects: 2597
Study: 22155903

Group type: EXPERIMENTAL
Intervention: Carraguard gel
Number of subjects: 1723

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1723

Group type: EXPERIMENTAL
Intervention: Carraguard (compliant users)
Number of subjects: 1723
Study: 19264879

Group type: EXPERIMENTAL
Intervention: Home-based Behavioral Family Systems Therapy (BFST)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group from previous study (n = 40)
Number of subjects: 18
Study: 16504002

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulphadoxine‐pyrimethamine (SP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chloroquine‐sulphadoxine‐pyrimethamine (CQ‐SP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amodiaquine‐sulphadoxine‐pyrimethamine (AQ‐SP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mefloquine‐sulphadoxine‐pyrimethamine (MQ‐SP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artesunate‐sulphadoxine‐pyrimethamine (AS‐SP)
Number of subjects: 0
Study: 15585437

Group type: EXPERIMENTAL
Intervention: Morphine sulfate 7.5 mg
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 11331959

Group type: EXPERIMENTAL
Intervention: Web-based technology for visual analysis and searchable storage of microarray image data
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Web-based technology for visual analysis
Number of subjects: 2
Study: 9549739

Group type: EXPERIMENTAL
Intervention: Intrathecal opioids (morphine and sufentanil) administered at L3-L4 after induction of anaesthesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (inhalation and intravenous narcotic anaesthesia)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intrathecal opioids
Number of subjects: 80
Study: 7890823

Group type: EXPERIMENTAL
Intervention: Asymptomatic HIV‐1 infection
Number of subjects: 44

Group type: COMPARATOR
Intervention: Seronegative (SN) controls
Number of subjects: 44
Study: 3190999

Group type: EXPERIMENTAL
Intervention: Quinapril hydrochloride
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 31451438

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31199342

Group type: EXPERIMENTAL
Intervention: Web-based happiness intervention with 1 of 14 possible 1-week activities (Sample 1)
Number of subjects: 2230

Group type: EXPERIMENTAL
Intervention: Web-based happiness intervention with 0, 2, 4, or 6 weeks of activities (Sample 2)
Number of subjects: 2230
Study: 28148632

Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 26511911

Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 30
Study: 23823086

Group type: EXPERIMENTAL
Intervention: Self-directed Teen Triple P intervention (10-week program with 10 modules of 1 hour each)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 79
Study: 21489749

Group type: EXPERIMENTAL
Intervention: Positive modification of interpretation bias
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Negative modification of interpretation bias
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Age-related effects
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Behavioral task response
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Avoidance behavior
Number of subjects: 103
Study: 19882583

Group type: EXPERIMENTAL
Intervention: Xal-Ease
Number of subjects: 211

Group type: COMPARATOR
Intervention: Dropper bottle
Number of subjects: 211
Study: 22884136

Group type: EXPERIMENTAL
Intervention: Arterial pressure‐based cardiac output (APCO) monitoring
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pulmonary artery catheter (PAC) monitoring
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: APCO and PAC monitoring
Number of subjects: 50
Study: 16422914

Group type: EXPERIMENTAL
Intervention: Intracavernous sodium nitroprusside (SNP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Papaverine/phentolamine (bimix)
Number of subjects: 40
Study: 12853194

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study: 10215671

Group type: EXPERIMENTAL
Intervention: alpha-methylnoradrenaline
Number of subjects: 6

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 6
Study: 8559866

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Relaxation Training
Number of subjects: 37

Group type: COMPARATOR
Intervention: Tricyclic Antidepressant Medication
Number of subjects: 37
Study: 2713219

Group type: EXPERIMENTAL
Intervention: Oral paracetamol (1 g)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Oral chloramphenicol (500 mg)
Number of subjects: 5
Study: 588391

Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 15

Group type: COMPARATOR
Intervention: Tubocurarine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Alcuronium
Number of subjects: 15
Study: 30418227

Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 65

Group type: COMPARATOR
Intervention: Antibiotics without L-carnitine (control)
Number of subjects: 65
Study: 30519904

Group type: EXPERIMENTAL
Intervention: Intervention to improve opioid prescribing practices in HIV outpatient clinics
Number of subjects: 0
Study: 28641912

Group type: EXPERIMENTAL
Intervention: Spirited Life intervention (2-year multicomponent health intervention including personal goal setting, monthly health coaching, online weight loss intervention, small grant, and workshops)
Number of subjects: 1114

Group type: EXPERIMENTAL
Intervention: Spirited Life intervention
Number of subjects: 1114

Group type: COMPARATOR
Intervention: 1-year waitlist control
Number of subjects: 1114

Group type: COMPARATOR
Intervention: 2-year waitlist control
Number of subjects: 1114
Study: 25212521

Group type: EXPERIMENTAL
Intervention: Home-based virtual reality system used for rehabilitation of the upper limb following stroke, advised to use 3 times a day for 20 minutes over 8 weeks.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Home-based virtual reality system
Number of subjects: 17
Study: 23570567

Group type: EXPERIMENTAL
Intervention: Couple-tailored print (CTP) intervention
Number of subjects: 168

Group type: COMPARATOR
Intervention: Generic print (GP) pamphlet
Number of subjects: 168
Study: 21623982

Group type: EXPERIMENTAL
Intervention: Trazodone 50 mg administered 30 min before bedtime for 7 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Trazodone on day 7
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 18274739

Group type: EXPERIMENTAL
Intervention: GRAPPA (acceleration factor 2, time reduction approximately 50%)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Non-accelerated MRI
Number of subjects: 25
Study: 16792770

Group type: EXPERIMENTAL
Intervention: Efalizumab 1.0 mg kg‐1 once weekly for 12 weeks
Number of subjects: 793

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 793
Study: 14509553

Group type: EXPERIMENTAL
Intervention: Nozovent (nasal valve dilator)
Number of subjects: 38
Study: 12125616

Group type: EXPERIMENTAL
Intervention: Testosterone injections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal testosterone levels
Number of subjects: 0
Study: 9358933

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (specifics not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytotoxic treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Revised QL form
Number of subjects: 0
Study: 1287015

Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg of famotidine (Group 3)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg of famotidine (Group 6)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg of diphenhydramine (Group 2)
Number of subjects: 126

Group type: COMPARATOR
Intervention: No drugs (Group 1)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Normal saline (Group 5)
Number of subjects: 126
Study: 4075934

Group type: EXPERIMENTAL
Intervention: Maternal caffeine ingestion (500 mg/day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Decaffeinated coffee (5 cups/day)
Number of subjects: 11
Study: 30165610

Group type: EXPERIMENTAL
Intervention: Canakinumab 50 mg, 150 mg, or 300 mg subcutaneously once every 3 months
Number of subjects: 4833

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4833
Study: 28821264

Group type: EXPERIMENTAL
Intervention: Early Access to ART for All (EAAA)
Number of subjects: 4501

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 4501
Study: 26304967

Group type: EXPERIMENTAL
Intervention: Peer coaching plus brief education
Number of subjects: 424

Group type: COMPARATOR
Intervention: Brief education alone
Number of subjects: 424
Study: 23210563

Group type: EXPERIMENTAL
Intervention: Electrostatic air filter
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo filter
Number of subjects: 37
Study: 21251861

Group type: EXPERIMENTAL
Intervention: Supervised, progressive exercise training and dietary counseling for 48 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 21
Study: 18453793

Group type: EXPERIMENTAL
Intervention: 8-item medication adherence scale
Number of subjects: 1367
Study: 16540560

Group type: EXPERIMENTAL
Intervention: Prednisone plus cyclosporine A (Pred+CsA)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Prednisone (Pred)
Number of subjects: 104
Study: 12649700

Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg bid
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8
Study: 11400948

Group type: EXPERIMENTAL
Intervention: Thalidomide (200-800 mg/day)
Number of subjects: 54
Study: 9489600

Group type: EXPERIMENTAL
Intervention: Valaciclovir, 1000 mg, given alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Valaciclovir, 1000 mg, given with digoxin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Digoxin given alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Digoxin given with valaciclovir (1000 mg three times/day for 8 days)
Number of subjects: 12
Study: 7875274

Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nitrazepam 10 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 3361221

Group type: EXPERIMENTAL
Intervention: Metronidazole 400 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29098392

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (6 µg/kg/h over 10 min followed by 0.2‐0.7 µg/kg/h)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Target-controlled infusion (initial target of 1.5 ng/ml using the Dyck model)
Number of subjects: 16
Study: 28131072

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 25450124

Group type: EXPERIMENTAL
Intervention: Reduction in depressive symptoms over the course of a 12-week trial
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Reduction in depressive symptoms
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Perceived functional disability
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Life satisfaction and mental well-being
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Physical well-being
Number of subjects: 124
Study: 23253744

Group type: EXPERIMENTAL
Intervention: Traditional blood pressure control rate (fixed BP target <140/90)
Number of subjects: 3355

Group type: EXPERIMENTAL
Intervention: CVR-adjusted blood pressure control rate (BP target <130/80 for very high CVR, <140/90 for high CVR, <160/100 for low CVR)
Number of subjects: 3355

Group type: EXPERIMENTAL
Intervention: Traditional blood pressure control rate
Number of subjects: 3355

Group type: EXPERIMENTAL
Intervention: CVR-adjusted blood pressure control rate
Number of subjects: 3355
Study: 21206288

Group type: EXPERIMENTAL
Intervention: Modified Smith-Petersen approach
Number of subjects: 48

Group type: COMPARATOR
Intervention: Hardinge approach
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 48
Study: 17412363

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Haloperidol and Risperidone
Number of subjects: 20
Study: 16441950

Group type: EXPERIMENTAL
Intervention: Isoflavone supplementation (50 mg/d)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 12664086

Group type: EXPERIMENTAL
Intervention: Chromium picolinate
Number of subjects: 489

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489
Study: 10474766

Group type: EXPERIMENTAL
Intervention: CD-ROM program based on the 'Sunny Days, Healthy Ways' curriculum
Number of subjects: 162
Study: 8764120

Group type: EXPERIMENTAL
Intervention: Regular milk products (calcium, 30 mM)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo milk products (calcium, 3 mM)
Number of subjects: 13
Study: 2059973

Group type: EXPERIMENTAL
Intervention: Fluoride dentifrices containing 1,000, 1,500, and 2,500 micrograms fluoride per gram as sodium monofluorophosphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 0
Study: 6282434

Group type: EXPERIMENTAL
Intervention: MER (methanol-extraction residue of Bacillus Calmette-Guerin) 400 mcg intradermally every six weeks
Number of subjects: 102

Group type: COMPARATOR
Intervention: No MER (control group)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: MER
Number of subjects: 102
Study: 30536595

Group type: COMPARATOR
Intervention: sacubitril/valsartan 200 mg
Number of subjects: 1438

Group type: COMPARATOR
Intervention: sacubitril/valsartan 400 mg
Number of subjects: 1438

Group type: COMPARATOR
Intervention: sacubitril/valsartan 200 mg and 400 mg
Number of subjects: 1438
Study: 29138199

Group type: EXPERIMENTAL
Intervention: Electrosclerotherapy (EST)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bleomycin sclerotherapy without electroporation
Number of subjects: 20

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 20
Study: 26574019

Group type: EXPERIMENTAL
Intervention: OLIVE
Number of subjects: 458

Group type: COMPARATOR
Intervention: SOYBEAN
Number of subjects: 458
Study: 24294604

Group type: EXPERIMENTAL
Intervention: Active laser (450 mW, 830 nm combined Ga‐Al‐As diode laser)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo irradiation
Number of subjects: 48
Study: 20673556

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 60
Study: 18438241

Group type: EXPERIMENTAL
Intervention: Strength and plyometric training (Group ST+P)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Strength training (Group ST)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (6 to 8 soccer sessions a week)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combined intervention group (ST and ST+P pooled)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study: 16546743

Group type: EXPERIMENTAL
Intervention: recombinant human epithelial growth factor (rhEGF)
Number of subjects: 48

Group type: COMPARATOR
Intervention: 500 kHz high‐frequency electromagnetic wave
Number of subjects: 48
Study: 15087598

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 5337
Study: 10955425

Group type: EXPERIMENTAL
Intervention: Monitoring plasma glucose up to four times daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: No monitoring of plasma glucose
Number of subjects: 70
Study: 9003479

Group type: EXPERIMENTAL
Intervention: CHOP
Number of subjects: 175

Group type: COMPARATOR
Intervention: ProMACE‐CytaBOM
Number of subjects: 175
Study: 1794889

Group type: EXPERIMENTAL
Intervention: Sugar-fortified milk formula
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard milk formula
Number of subjects: 130
Study: 6337655

Group type: EXPERIMENTAL
Intervention: High dose bolus 6‐methylprednisolone (BMPr) at 20 mg/kg/day i.v. for the first 3 days, 10 mg/kg/day i.v. for the following 4 days, then tapered to 1 mg/kg/day.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High dose bolus 6‐methylprednisolone (BMPr)
Number of subjects: 19
Study: 2874773

Group type: EXPERIMENTAL
Intervention: Topically applied betamethasone valerate
Number of subjects: 0
Study: 31462688

Group type: EXPERIMENTAL
Intervention: Baseline mean total activity
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Baseline LPA
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Baseline total MVPA
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Baseline long-bout MVPA
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Baseline weight
Number of subjects: 886
Study: 29987746

Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields (TTF) therapy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Temozolomide alone
Number of subjects: 106
Study: 27543472

Group type: EXPERIMENTAL
Intervention: Coconut oil (Group I)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sunflower oil (Group II)
Number of subjects: 200